Leukocyte interferon (IFN alpha) in patients with epithelial ovarian carcinoma. 1983

R S Freedman, and J U Gutterman, and J T Wharton, and F N Rutledge

Human leukocyte interferon (IFN alpha) was administered to 15 patients with epithelial ovarian carcinoma after previous chemotherapy or therapeutic irradiation. One objective response was observed. Three patients had possible stable disease for up to 6 months, including two patients who were re-explored 6 months after commencing IFN alpha and one patient who was observed to have a less than 50% reduction in her tumor diameters. Three of seven patients demonstrated clinical responses to subsequent chemotherapy, indicating an absence of resistance to subsequent chemotherapy. Toxicity included the relatively mild symptoms of anorexia, lassitude, and diarrhea. Malabsorption was observed in one patient. Platelet depression and abnormal enzyme liver functions were also observed more frequently following IFN alpha. No life-threatening toxicity was observed.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D001772 Blood Cell Count The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES. Blood Cell Number,Blood Count, Complete,Blood Cell Counts,Blood Cell Numbers,Blood Counts, Complete,Complete Blood Count,Complete Blood Counts,Count, Blood Cell,Count, Complete Blood,Counts, Blood Cell,Counts, Complete Blood,Number, Blood Cell,Numbers, Blood Cell
D002277 Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for "cancer." Carcinoma, Anaplastic,Carcinoma, Spindle-Cell,Carcinoma, Undifferentiated,Carcinomatosis,Epithelial Neoplasms, Malignant,Epithelioma,Epithelial Tumors, Malignant,Malignant Epithelial Neoplasms,Neoplasms, Malignant Epithelial,Anaplastic Carcinoma,Anaplastic Carcinomas,Carcinoma, Spindle Cell,Carcinomas,Carcinomatoses,Epithelial Neoplasm, Malignant,Epithelial Tumor, Malignant,Epitheliomas,Malignant Epithelial Neoplasm,Malignant Epithelial Tumor,Malignant Epithelial Tumors,Neoplasm, Malignant Epithelial,Spindle-Cell Carcinoma,Spindle-Cell Carcinomas,Tumor, Malignant Epithelial,Undifferentiated Carcinoma,Undifferentiated Carcinomas
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000469 Alkaline Phosphatase An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.1.
D001219 Aspartate Aminotransferases Enzymes of the transferase class that catalyze the conversion of L-aspartate and 2-ketoglutarate to oxaloacetate and L-glutamate. EC 2.6.1.1. Aspartate Aminotransferase,Aspartate Transaminase,Glutamic-Oxaloacetic Transaminase,SGOT,Aspartate Apoaminotransferase,Glutamate-Aspartate Transaminase,L-Aspartate-2-Oxoglutarate Aminotransferase,Serum Glutamic-Oxaloacetic Transaminase,Aminotransferase, Aspartate,Aminotransferase, L-Aspartate-2-Oxoglutarate,Aminotransferases, Aspartate,Apoaminotransferase, Aspartate,Glutamate Aspartate Transaminase,Glutamic Oxaloacetic Transaminase,Glutamic-Oxaloacetic Transaminase, Serum,L Aspartate 2 Oxoglutarate Aminotransferase,Serum Glutamic Oxaloacetic Transaminase,Transaminase, Aspartate,Transaminase, Glutamate-Aspartate,Transaminase, Glutamic-Oxaloacetic,Transaminase, Serum Glutamic-Oxaloacetic

Related Publications

R S Freedman, and J U Gutterman, and J T Wharton, and F N Rutledge
January 1985, Cancer treatment reports,
R S Freedman, and J U Gutterman, and J T Wharton, and F N Rutledge
September 1991, European journal of haematology,
R S Freedman, and J U Gutterman, and J T Wharton, and F N Rutledge
July 1990, Clinical and experimental immunology,
R S Freedman, and J U Gutterman, and J T Wharton, and F N Rutledge
April 1982, American journal of clinical oncology,
R S Freedman, and J U Gutterman, and J T Wharton, and F N Rutledge
August 1993, Gynecologic oncology,
R S Freedman, and J U Gutterman, and J T Wharton, and F N Rutledge
April 1988, Lancet (London, England),
R S Freedman, and J U Gutterman, and J T Wharton, and F N Rutledge
December 1983, The Journal of urology,
R S Freedman, and J U Gutterman, and J T Wharton, and F N Rutledge
June 1982, Journal of immunology (Baltimore, Md. : 1950),
R S Freedman, and J U Gutterman, and J T Wharton, and F N Rutledge
July 2010, Nihon rinsho. Japanese journal of clinical medicine,
R S Freedman, and J U Gutterman, and J T Wharton, and F N Rutledge
August 2005, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!